X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA STRIDES SHASUN LTD ALEMBIC PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 24.4 37.2 65.6% View Chart
P/BV x 6.8 0.9 738.5% View Chart
Dividend Yield % 0.7 1.1 64.4%  

Financials

 ALEMBIC PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-17
ALEMBIC PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs7921,275 62.1%   
Low Rs443918 48.3%   
Sales per share (Unadj.) Rs167.0389.6 42.9%  
Earnings per share (Unadj.) Rs38.228.0 136.4%  
Cash flow per share (Unadj.) Rs42.048.9 85.9%  
Dividends per share (Unadj.) Rs4.004.50 88.9%  
Dividend yield (eoy) %0.60.4 157.9%  
Book value per share (Unadj.) Rs84.9303.1 28.0%  
Shares outstanding (eoy) m188.5289.42 210.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.72.8 131.3%   
Avg P/E ratio x16.239.2 41.3%  
P/CF ratio (eoy) x14.722.4 65.6%  
Price / Book Value ratio x7.33.6 201.0%  
Dividend payout %10.516.1 65.1%   
Avg Mkt Cap Rs m116,38398,036 118.7%   
No. of employees `000NA5.8 0.0%   
Total wages/salary Rs m4,2145,881 71.6%   
Avg. sales/employee Rs ThNM6,005.9-  
Avg. wages/employee Rs ThNM1,014.0-  
Avg. net profit/employee Rs ThNM431.2-  
INCOME DATA
Net Sales Rs m31,48734,834 90.4%  
Other income Rs m551,686 3.3%   
Total revenues Rs m31,54236,520 86.4%   
Gross profit Rs m10,0606,428 156.5%  
Depreciation Rs m7221,872 38.6%   
Interest Rs m372,269 1.6%   
Profit before tax Rs m9,3563,973 235.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-24 -41.7%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m2,160470 459.6%   
Profit after tax Rs m7,1942,501 287.7%  
Gross profit margin %31.918.5 173.1%  
Effective tax rate %23.111.8 195.2%   
Net profit margin %22.87.2 318.2%  
BALANCE SHEET DATA
Current assets Rs m15,06638,165 39.5%   
Current liabilities Rs m7,67430,402 25.2%   
Net working cap to sales %23.522.3 105.3%  
Current ratio x2.01.3 156.4%  
Inventory Days Days6777 86.6%  
Debtors Days Days41104 38.9%  
Net fixed assets Rs m8,23737,639 21.9%   
Share capital Rs m377894 42.2%   
"Free" reserves Rs m15,41626,210 58.8%   
Net worth Rs m16,00527,105 59.1%   
Long term debt Rs m016,377 0.0%   
Total assets Rs m24,59481,168 30.3%  
Interest coverage x255.22.8 9,278.9%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.4 298.3%   
Return on assets %29.45.9 500.3%  
Return on equity %44.99.2 487.2%  
Return on capital %58.712.1 486.9%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81113,465 132.3%   
Fx outflow Rs m5,3184,076 130.5%   
Net fx Rs m12,4939,389 133.0%   
CASH FLOW
From Operations Rs m9,3042,881 322.9%  
From Investments Rs m-3,105-7,051 44.0%  
From Financial Activity Rs m-1,9593,382 -57.9%  
Net Cashflow Rs m4,240-788 -538.4%  

Share Holding

Indian Promoters % 74.1 27.7 267.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 37.8 7.7%  
FIIs % 9.1 8.6 105.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 25.9 53.7%  
Shareholders   49,328 56,241 87.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 14, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS